IP Library Granted Patent US 10,676,504
Granted Patent B2
US 10,676,504 · App. 15/555,755 · Granted Jun 9, 2020

Method for preparing largazole analogs and uses thereof

Inventors: Robert M. Williams (Fort Collins, CO); James E. Bradner (Weston, MA); Dane Clausen (Rahway, NJ); Olaf G. Wiest (South Bend, IN); Tenaya L. Newkirk (Denver, CO); Albert A. Bowers (Chapel Hill, NC); Jennifer Marie Guerra (Henderson, NV)
Assignees: Colorado State University Research Foundation; Dana-Farber Cancer Institute, Inc.; University of Notre Dame du Lac
C07K5/06052A61K31/429A61K31/437A61K38/05A61K45/06C07B59/008C07D513/18C07B2200/05
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,676,504
App. No.
15/555,755
Granted
Jun 9, 2020
Kind
B2
Abstract

Analogs of largazole are described herein. Methods of treating cancer and blood disorders using largazole and largazole analogs and pharmaceutical compositions comprising the same are additionally described herein. Methods for preparing largazole analogs are likewise described.

Claims (13)

1. A compound of Formula (A)

or a pharmaceutically acceptable salt, solvate, clathrate, prodrug, or stereoisomer thereof.

2. A method for treating histone deacetylase (HDAC) responsive cancer in a subject, comprising inhibiting HDAC by administering to the subject a therapeutically effective amount of the compound of claim 1 .

3. The method of claim 2 , further comprising administering to said subject an additional form of therapy for cancer.

4. A method for treating a histone deacetylase (HDAC) responsive blood disorder in a subject, comprising inhibiting HDAC by administering to the subject a therapeutically effective amount of the compound of claim 1 .

5. The method of claim 4 , wherein the blood disorder is at least one of a hemoglobinopathy or a thalassemia.

6. The method of claim 4 , further comprising administering to said subject an additional form of therapy for said blood disorder.

7. The method of claim 2 , wherein the subject is human.

8. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 and at least one pharmaceutically acceptable excipient wherein the pharmaceutical composition is useful for treating cancer in a subject.

9. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 and at least one pharmaceutically acceptable excipient wherein the pharmaceutical composition is useful for treating a blood disorder in a subject.

10. The pharmaceutical composition of claim 9 , wherein the blood disorder is at least one of a hemoglobinopathy or a thalassemia.

11. The pharmaceutical composition of claim 8 , wherein the subject is human.

12. The compound of claim 1 , further comprising a radiolabel.

Assignments (4)
CONFIRMATORY LICENSE Recorded Sep 13, 2021
From: COLORADO STATE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 057493/0410 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2017
From: WIEST, OLAF G
To: UNIVERSITY OF NOTRE DAME DU LAC
Reel/Frame 044383/0843 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2017
From: WILLIAMS, ROBERT M; CLAUSEN, DANE; BOWERS, ALBERT A; NEWKIRK, TENAYA L; GUERRA, JENNIFER MARIE
To: COLORADO STATE UNIVERSITY RESEARCH FOUNDATION
Reel/Frame 044044/0850 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2017
From: BRADNER, JAMES E
To: DANA-FARBER CANCER INSTITUTE, INC.
Reel/Frame 044044/0867 →
Continuity (2)
Provisional Application 62129748 · Mar 6, 2015
Related Publication 20180044376A1 · Feb 15, 2018
Cited By (1)
US 12,227,522